

Inhibitors of NS5A for Treatment of HCV Infection


Jean-Francois Brazeau[†] and Gerard Rosse^{*,†,‡}[†]Structure Guided Chemistry, Dart Neuroscience LLC, 7473 Lusk Boulevard, San Diego, California 92121, United States[‡]Adjunct Associate Professor, Department of Pharmacology and Physiology, College of Medicine, Drexel University, New College Building, 245 North 15th Street, Philadelphia, Pennsylvania 19102, United States

Title: Inhibitors of NSSA for Treatment of HCV Infection
Patent/Patent Application Number: WO2013098320
Priority Application: EP 2012-152267
Inventors: Vandyck, K.; Raboisson, P. J.-M. B.
Assignee Company: Janssen R&D, Ireland
Disease Area: HCV infection
Summary: The present application claims quinazolinone derivatives as novel inhibitors of hepatitis C virus.
Important Compound Classes:

Publication date: July 4, 2013
Priority date: January 24, 2012

Biological Target: HCV NSSA protein

Key Structures:



Biological Assay: The replicon assay was developed using transfected cell line Huh-7 Luc/Neo.
Pharmacological Data: The EC₅₀ values from the assay are reported for 15 examples.

	HCV replicon assay (EC ₅₀ , nM)
Compound 1	0.026
Compound 4	0.008
Compound 10	0.006
Compound 15	0.006

Synthesis: 15 compounds were prepared.

AUTHOR INFORMATION

Corresponding Author

*E-mail: grosse@dartneuroscience.com.

Notes

The authors declare no competing financial interest.

Special Issue: HCV Therapies

Received: September 17, 2013

Published: September 24, 2013